Skip to main content

CORRECTION article

Front. Immunol., 06 September 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1269596

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

This article is a correction to:

  1. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

    1. Read original article
Zhimin Zeng,,&#x;Zhimin Zeng1,2,3†Xiaoying Qian,&#x;Xiaoying Qian4,5†Fanrong Liu&#x;Fanrong Liu6†Yong Wang,Yong Wang4,5Yong YuanYong Yuan7Chen Fang,Chen Fang4,5Xinwei Zhang,Xinwei Zhang4,5Shangkun Yuan,Shangkun Yuan4,5Renfang Chen,Renfang Chen4,5Biao Yu,Biao Yu4,5Tong Wang,Tong Wang4,5Yan YinYan Yin8Yong Li,*Yong Li4,5*Anwen Liu,,*Anwen Liu1,2,3*
  • 1Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
  • 2Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China
  • 3Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China
  • 4Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
  • 5Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
  • 6Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 7Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 8Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China

A Corrigendum on:
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

By Zheng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y and Liu A (2022)  13:956982. doi: 10.3389/fimmu.2022.956982

In the published article, there was an error in the author list, and author Anwen Liu and Zhimin Zeng was erroneously excluded. The corrected author list appears below.

Zhimin Zeng1,2,3†, Xiaoying Qian4,5†, Fanrong Liu6†, Yong Wang4,5, Yong Yuan7, Chen Fang4,5, Xinwei Zhang4,5, Shangkun Yuan4,5, Renfang Chen4,5, Biao Yu4,5, Tong Wang4,5, Yan Yin8, Yong Li4,5* and Anwen Liu1,2,3*

The Author contributions have also been amended to: AL and YL co-designed the research. ZZ, XQ, and FL made a significant contribution to the data integration and analysis. ZZ provided patients’ information and data analysis. XQ drew up the manuscript. FL and YW processed the figures and tables. YYu, CF, XZ, and SY collected the outcome. RC, BY, TW and YYi followed up on the case. All authors contributed to the article and approved the submitted version.

In the published article, there was an error. The approval of the institutional ethics committee of Second Affiliated Hospital of Nanchang University was not added to the ethics statement.

A correction has been made to Ethics statement. This sentence previously stated:

“This study was reviewed and approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.

The corrected sentence appears below:

“This study was reviewed and approved by the institutional ethics committee of the Second Affiliated Hospital of Nanchang University and the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pulmonary sarcomatoid carcinoma, immune checkpoint inhibitors, immunotherapy, anlotinib, camrelizumab, tislelizumab

Citation: Zeng Z, Qian X, Liu F, Wang Y, Yuan Y, Fang C, Zhang X, Yuan S, Chen R, Yu B, Wang T, Yin Y, Li Y and Liu A (2023) Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. Front. Immunol. 14:1269596. doi: 10.3389/fimmu.2023.1269596

Received: 30 July 2023; Accepted: 24 August 2023;
Published: 06 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Anwen Liu, awliu666@163.com; Yong Li, liyongcsco@email.ncu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.